When I google this; I got a link to what appears to be a IDRA press release. The phase 2 trial locations are in Netherland with 32 patients receiving 1:1:1:1 ratio on different dosage and placebo (sugar pill). My questions are. Why Netherland? The previous (2012) phase 2a of IMO-3100 was done in 11 sites in US with 44 patients; so why did they move the new version of the trial to Europe and with fewer patients? My only concern is the different standard of care comparing to US if any and how that would impact the result. Could someone please confirm the trial location and number of patients? Thanks.
I have done some basic DD and have been watching this stock since Aug 2012; but I really need to understand the history of this company before investing it. Based on the data available from my broker account, CLDX has been trading stock since at least June 1 1986. It has been almost 28 years now. Yet this company neither has a single product on the market nor close to having one on the market. Yes, they have many pipelines; but what is the realistic timeline for these products to get approval and go to market? Also, why do they want to have so many products? Why not focus with fewer pipeline and get them to FDA for approval and then start making money? The point is; it has been almost 28 years and not even one product on the market, and they just announced result of a pre-clinical trial. Please enlighten me all you bio stock gurus out there. What’s the history of this company? Is this really a good company to invest all the way to retirement?